U.S. market Closed. Opens in 8 hours 44 minutes

VERA | Vera Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 49.23 - 51.23
52 Week Range 13.09 - 51.61
Beta 1.18
Implied Volatility 55.03%
IV Rank 7.94%
Day's Volume 627,570
Average Volume 771,525
Shares Outstanding 63,323,100
Market Cap 3,137,659,605
Sector Healthcare
Industry Biotechnology
IPO Date 2021-05-14
Valuation
Profitability
Growth
Health
P/E Ratio -18.98
Forward P/E Ratio N/A
EPS -2.61
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 72
Country USA
Website VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
*Chart delayed
Analyzing fundamentals for VERA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see VERA Fundamentals page.

Watching at VERA technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on VERA Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙